Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147898 | 1.00 | L3MBTL1 (0.46) | L3MBTL1KMT2ADPP4SIGMAR1PDE4B | |
| SCHEMBL147896 | 1.00 | L3MBTL1 (0.46) | L3MBTL1KMT2ADPP4SIGMAR1PDE4B | |
| SCHEMBL463520 | 0.93 | KMT2A (0.44) | L3MBTL1KMT2ADPP4SIGMAR1PDE4B | |
| SCHEMBL463519 | 0.93 | KMT2A (0.44) | L3MBTL1KMT2ADPP4SIGMAR1PDE4B | |
| SCHEMBL5924028 | 0.92 | KMT2A (0.45) | L3MBTL1KMT2ADPP4SIGMAR1PDE4B | |
| SCHEMBL143625 | 0.90 | MC1R (0.49) | L3MBTL1KMT2ASIGMAR1DRD2DRD3 | |
| SCHEMBL147672 | 0.90 | KMT2A (0.48) | L3MBTL1KMT2ADPP4SIGMAR1CHRM4 | |
| SCHEMBL147670 | 0.90 | KMT2A (0.48) | L3MBTL1KMT2ADPP4SIGMAR1CHRM4 | |
| SCHEMBL143626 | 0.90 | MC1R (0.49) | L3MBTL1KMT2ASIGMAR1DRD2DRD3 | |
| SCHEMBL147671 | 0.90 | KMT2A (0.48) | L3MBTL1KMT2ADPP4SIGMAR1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2406256-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| US-20060264433-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | L3MBTL1 4277/4885KMT2A 3204/4885DPP4 407/4885 |
| US-20060264433-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | L3MBTL1 3609/4885KMT2A 3336/4885DPP4 1/4885 |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | L3MBTL1 3426/4885KMT2A 2799/4885DPP4 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.